PMID- 27215077
OWN - NLM
STAT- MEDLINE
DCOM- 20160609
LR  - 20191113
IS  - 1433-6510 (Print)
IS  - 1433-6510 (Linking)
VI  - 62
IP  - 4
DP  - 2016
TI  - Elevated Serum Levels of Sclerostin are Associated with High Disease Activity and 
      Functional Impairment in Patients with Axial Spondyloarthritis.
PG  - 589-97
AB  - BACKGROUND: Recent research suggests that biomarkers may be useful in assessing 
      disease activity, structural damage, and response to therapy in axial 
      spondyloarthritis (axSpA). Our study aims at evaluating the relationship between 
      inflammation and bone remodeling markers and variables assessing disease activity 
      and functional disability in patients with axSpA. METHODS: Serum levels of 
      sclerostin, matrix metalloproteinase-3 (MMP-3), interleukin-17 (IL-17), and IL-23 
      were measured in 60 patients with axSpA and 20 healthy controls. Disease activity 
      was evaluated using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 
      Ankylosing Spondylitis Disease Activity Score (ASDAS), C-reactive protein (CRP), 
      and erythrocyte sedimentation rate (ESR). Functional status was assessed by Bath 
      Ankylosing Spondylitis Function Index (BASFI) and measures of spinal mobility. 
      RESULTS: Sclerostin levels were more elevated in axSpA patients with high disease 
      activity than in those with low disease activity and in controls. They were 
      significantly correlated with BASFI values (r = 0.29, p = 0.03) and measures of 
      spinal mobility, but not with the classical markers of disease activity (BASDAI, 
      ASDAS, CRP, and ESR). Although both MMP-3 and IL-17 levels were elevated in 
      patients with active disease, they were not correlated with markers of disease 
      activity or with functional disability. The levels of sclerostin, MMP-3, IL-17, 
      and IL-23 were similar in axSpA patients and healthy controls. CONCLUSIONS: 
      Elevated levels of sclerostin, MMP-3, and IL-17 were observed in axSpA patients 
      with active disease, suggesting their potential role in assessing disease 
      activity. In axSpA patients, sclerostin levels might be equally influenced by 
      inflammation and level of physical activity. Further studies are required to 
      confirm our findings in order to understand their clinical value.
FAU - Muntean, Laura
AU  - Muntean L
FAU - Lungu, Andreea
AU  - Lungu A
FAU - Gheorghe, Simona R
AU  - Gheorghe SR
FAU - Valeanu, Madalina
AU  - Valeanu M
FAU - Craciun, Alexandra M
AU  - Craciun AM
FAU - Felea, Ioana
AU  - Felea I
FAU - Petcu, Ana
AU  - Petcu A
FAU - Filipescu, Ileana
AU  - Filipescu I
FAU - Simon, Siao-Pin
AU  - Simon SP
FAU - Rednic, Simona
AU  - Rednic S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Clin Lab
JT  - Clinical laboratory
JID - 9705611
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukin-23)
RN  - 0 (Proteins)
RN  - 0 (sclerotin)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adult
MH  - Female
MH  - Humans
MH  - Interleukin-17/blood
MH  - Interleukin-23/blood
MH  - Male
MH  - Matrix Metalloproteinase 3/blood
MH  - Middle Aged
MH  - Proteins/*analysis
MH  - Severity of Illness Index
MH  - Spondylarthritis/*blood
EDAT- 2016/05/25 06:00
MHDA- 2016/06/10 06:00
CRDT- 2016/05/25 06:00
PHST- 2016/05/25 06:00 [entrez]
PHST- 2016/05/25 06:00 [pubmed]
PHST- 2016/06/10 06:00 [medline]
AID - 10.7754/clin.lab.2015.150801 [doi]
PST - ppublish
SO  - Clin Lab. 2016;62(4):589-97. doi: 10.7754/clin.lab.2015.150801.